logo
Ring Energy, Inc. (REI): Among the Cheap Growth Stocks to Buy Now

Ring Energy, Inc. (REI): Among the Cheap Growth Stocks to Buy Now

Yahoo08-03-2025

We recently compiled a list of the . In this article, we are going to take a look at where Ring Energy, Inc. (NYSEAMERICAN:REI) stands against the other cheap growth stocks.
Growth stocks—those of companies expected to grow at an above-average rate compared to other firms—have historically exhibited cyclical performance patterns. For instance, during the 1990s dot-com era, growth stocks did well, as reported by Hartford Funds.
From 2014 to 2024, growth stocks surged ahead of other market segments, with the Russell Growth Index delivering an annualized return of 17%. This return was more than double that of value stocks (8%), small-cap stocks (8%), and international equities (5%). The broader market, which itself has been heavily influenced by large-cap tech companies, delivered a 13% annualized return. This further amplifies the performance of growth-oriented investments.
This growth-driven rally had profound effects on the composition of traditionally balanced portfolios. A standard 60/40 portfolio (60% equities, 40% bonds) that was left untouched over this period would have seen its growth stock allocation more than double from 20% to 42%, crowding out other investment segments.
As financial markets navigate a stabilizing interest rate environment and moderating inflation, investors are revisiting growth equities with renewed focus. Cheap growth stocks have reemerged as a strategic play in 2025. With the Federal Reserve pausing its tightening cycle and inflation cooling to 2.9% (down from 2022's 9.1% peak), the macroeconomic landscape now favors selective risk-taking.
Analysts suggest that stocks with a price-to-earnings (P/E) ratio below 15x often present attractive investment opportunities. These stocks may offer a combination of growth potential, driven by strong revenue and earnings expansion, as well as resilience, enabling them to perform well even in uncertain macroeconomic conditions.
As Charlie Munger aptly said, "All intelligent investing is value investing—acquiring more than you are paying for. You must value the business in order to value the stock." This mindset aligns perfectly with identifying companies with lower P/E ratios, where the value they offer can outweigh the price being paid. Given this, we will take a look at some of the best cheap growth stocks to invest in.
To compile a list of the 10 Cheap Growth Stocks to Buy Now, we first utilized Finviz stock screener to identify US companies with a Price-to-Earnings (P/E) ratio of 15 or lower and an implied sales growth of over 20% over the last five years. From this selection, we then ranked the stocks according to their P/E ratio.
At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
An oil rig under construction in the middle of a lake, its lights reflecting on the surrounding water.
Price to Earnings ratio: 2.12
Ring Energy, Inc. (NYSEAMERICAN:REI) is an oil and gas exploration and production company focused on developing its Permian Basin assets in Texas.
On Feb 26, 2025 Ring Energy, Inc. (NYSEAMERICAN:REI) announced a $100 million acquisition of Lime Rock Resources IV, LP's Central Basin Platform (CBP) assets. This further strengthens its Permian Basin footprint. The acquisition, consisting of $80 million in upfront cash, a $10 million deferred payment, and up to 7.4 million shares of common stock, is expected to boost production, improve operational synergies, and enhance free cash flow generation. The newly acquired 17,700 net acres contribute 2,300 barrels of oil equivalent per day (over 80% oil) of low-decline production across 101 gross wells.
Ring Energy, Inc. (NYSEAMERICAN:REI) reported record sales of 20,108 barrels of oil equivalent per day (66% oil) for Q3 2024, exceeding guidance, with oil sales of 13,204 barrels of oil per day. The company posted a net income of $33.9 million and Adjusted Net Income of $13.4 million, reflecting strong operational efficiency. It successfully reduced its debt by $15 million, ending Q3 with $392 million in outstanding borrowings, while boosting its liquidity to $208 million.
Overall REI ranks 1st on our list of the cheap growth stocks to buy now. While we acknowledge the potential of REI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REI but that trades at less than 5 times its earnings, check out our report about the .
READ NEXT: 20 Best AI Stock To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025

Yahoo

time19 minutes ago

  • Yahoo

Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025

NEW YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025, an increase of $1.1 billion from assets under management of $87.5 billion at April 30, 2025. The increase was due to market appreciation of $1.3 billion, partially offset by distributions of $150 million and net outflows of $88 million. Assets Under Management (unaudited) ($ in millions) AUM Net MarketAUM By investment vehicle: 4/30/2025 Flows App/(Dep) Distributions 5/31/2025 Institutional Accounts: Advisory $19,937 $10 $352 - $20,299 Subadvisory 14,091 (19) 306 (57) 14,321 Total Institutional Accounts 34,028 (9) 658 (57) 34,620 Open-end Funds 42,210 (80) 510 (42) 42,598 Closed-end Funds 11,271 1 176 (51) 11,397 Total AUM $87,509 ($88) $1,344 ($150) $88,615 About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore. View original content: SOURCE Cohen & Steers, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Calavo (NASDAQ:CVGW) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops 15.3%
Calavo (NASDAQ:CVGW) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops 15.3%

Yahoo

time21 minutes ago

  • Yahoo

Calavo (NASDAQ:CVGW) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops 15.3%

Fresh produce company Calavo Growers (NASDAQ:CVGW) fell short of the market's revenue expectations in Q1 CY2025 as sales rose 3.3% year on year to $190.5 million. Its non-GAAP profit of $0.40 per share was 25% below analysts' consensus estimates. Is now the time to buy Calavo? Find out in our full research report. Revenue: $190.5 million vs analyst estimates of $192.8 million (3.3% year-on-year growth, 1.1% miss) Adjusted EPS: $0.40 vs analyst expectations of $0.53 (25% miss) Adjusted EBITDA: $11.4 million vs analyst estimates of $14.74 million (6% margin, 22.7% miss) Operating Margin: 4%, in line with the same quarter last year Market Capitalization: $493.7 million 'Our second fiscal quarter performance reflects the strength of our commercial strategy and disciplined operational execution amid continued volatility in the avocado market. Revenue grew year-over-year, driven by strong pricing performance,' said Lee Cole, President and Chief Executive Officer of Calavo Growers, Inc. A trailblazer in the avocado industry, Calavo Growers (NASDAQ:CVGW) is a pioneering California-based provider of high-quality avocados and other fresh food products. A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. With $694.5 million in revenue over the past 12 months, Calavo is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. As you can see below, Calavo's demand was weak over the last three years. Its sales fell by 15.8% annually, a tough starting point for our analysis. This quarter, Calavo's revenue grew by 3.3% year on year to $190.5 million, falling short of Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to decline by 1.8% over the next 12 months. it's tough to feel optimistic about a company facing demand difficulties. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. Calavo broke even from a free cash flow perspective over the last two years, giving the company limited opportunities to return capital to shareholders. We struggled to find many positives in these results as Calavo fell short of Wall Street's estimates across all key metrics. Overall, this quarter could have been better. The stock traded down 15.3% to $23.42 immediately after reporting. The latest quarter from Calavo's wasn't that good. One earnings report doesn't define a company's quality, though, so let's explore whether the stock is a buy at the current price. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market
MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market

Business Upturn

time21 minutes ago

  • Business Upturn

MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market

IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) — MUSE Microscopy, Inc., a pioneer in digital pathology innovation, today announced the formation of MUSE Veterinary Digital Pathology, LLC, a wholly-owned subsidiary focused on transforming pathology through point-of-care service. This initiative aims to provide same-day results for tissue biopsies. This new service will provide the gold standard of patient care allowing veterinarians to deliver pet parents with diagnosis, prognosis, and treatment plans efficiently using the SmartPath MUSE Technology™ (SmartPath)* Platform. The strategic move signifies MUSE's formal entry into the veterinary health market, bringing point-of-care and real-time diagnostic imaging to specialty, emergency, and family veterinary practices nationwide. Utilizing the unique capabilities of SmartPath for rapid, non-destructive tissue imaging, MUSE Veterinary Digital Pathology empowers veterinarians to make real-time treatment decisions, marking a significant innovation in tissue pathology in the past century. Matthew Nunez, CEO of MUSE Microscopy, will lead MUSE Veterinary Digital Pathology supported by a seasoned executive, Darin Nelson, who has a proven track record in building and scaling veterinary diagnostic companies. He acquired more than 800 animal hospitals for both VCA and Thrive Pet Healthcare and helped pet insurer Trupanion go public. Darin will join the company as President. Dr. Jeffrey Edwards, DVM, MPH, MRVCS, DAVCP, a clinical leader in veterinary diagnostics in his storied career, has been appointed as Chief Medical Officer overseeing the anatomic pathology team and the translational adoption of our innovative technology in veterinary practices nationwide.. Advertisement 'This launch represents a natural and strategic expansion of our technology platform,' stated Matthew Nunez. 'The veterinary sector is primed for innovation in diagnostic speed and precision. With MUSE Veterinary Digital Pathology, we are delivering state-of-the-art digital pathology directly to the point-of-care, empowering veterinarians to deliver faster diagnoses, reduce unnecessary delays, and elevate patient care.' MUSE Veterinary Digital Pathology will initially target specialty and emergency practices and large general practices, expected to commence in Q4 2025. The platform's intraoperative capabilities, same day results, and SmartPath's tissue-to-digital imaging will provide real-time surgical margin assessments and tissue diagnostics without reliance on current conventional slide-based workflows. 'This is about putting powerful diagnostic tools directly into the hands of veterinarians when and where they need them most,' stated Darin Nelson. 'Our goal is to enable faster decision-making, minimize wait times, and ultimately improve clinical outcomes for animal patients.' 'Veterinary medicine is long overdue for this level of innovation,' added Dr. Jeffrey Edwards. 'With our groundbreaking technology, we can reduce the delay in receiving biopsy results currently requiring couriers and 3-7 days down to same day diagnosis, changing the entire dynamic of medical management and clinical decision making as well as alleviated owner anxiety of waiting.' MUSE Veterinary Digital Pathology will operate independently while leveraging MUSE Microscopy's existing infrastructure, regulatory framework, personnel, and proprietary imaging technologies. The company anticipates additional announcements in the coming months, including pilot partnerships and distribution opportunities across the U.S. and internationally. About MUSE Microscopy, Inc. MUSE Microscopy is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath)*, is a slide-free direct-to-digital imaging platform that aims to transform the patient's experience and provide healthcare professionals with quick diagnostic information through digital imaging. To learn more, you can visit their website at or find them on social media platforms such as Twitter, Facebook, and LinkedIn. *Pending FDA approval. Limits on Accuracy This press release is intended to provide information about MUSE Microscopy, Inc.'s research and potential product. Information is believed to be accurate at the time it is created. However, like any printed material, information may become outdated over time. Information may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice. There may also be improvements or changes in the products and services described in this press release at any time without notice. It is important that you rely on the advice of an appropriate professional. Nothing contained in any presentation is to be construed as medical, legal, investment, financial, or other advice. This information is not intended to be a substitute for such advice. MUSE Microscopy, Inc., does not endorse any specific techniques or methods of treatment. Individuals are advised to consult their health care professionals for full information about the potential adverse reactions from use of the medical technologies discussed in this press release. We will use reasonable efforts to include accurate and up-to-date information on the website, but MUSE Microscopy, Inc. makes no warranties or representations as to its accuracy. Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans, prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. MEDIA CONTACT: Matthew Nuñez Tel: 949.813.6121 [email protected] Source: MUSE Microscopy, Inc. Join the Evolution. Embrace the Future. #DigitalPathology #SlideFreeRevolution #SmartPathMUSE For more information about MUSE Microscopy and its innovative technologies, please visit Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store